Oncology Corporate Profile
Novocure is dedicated to the development of tumor treating fields (TTF) therapy, a new weapon for patients and physicians in the battle against cancer. TTF therapy is a breakthrough anti-mitotic treatment that attempts to slow or reverse tumor progression by inducing tumor cell death prior to division. Physicians deliver TTF therapy using a portable, non-invasive medical device.
|NovoTTF-100A System™||medical device||The NovoTTF-100A System is intended as a treatment for adult patients (22|
years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device
is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|NovoTTF-100A System? (+ temozolomide)||tumor treating fields (TTF) therapy||1st line metastatic Glioblastoma Multiforme (GBM)||III|
|NovoTTF-100L System? (+ pemetrexed)||tumor treating fields (TTF) therapy||Pancreatic cancer||I|
|NovoTTF-100L System? (+ pemetrexed)||tumor treating fields (TTF) therapy||1st line metastatic Non Small Cell Lung Cancer (NSCLC)||II|
View additional information on product candidates here »